يعرض 61 - 80 نتائج من 37,739 نتيجة بحث عن '(( a non decrease ) OR ((( 20 mean decrease ) OR ( 50 ((ng decrease) OR (a decrease)) ))))', وقت الاستعلام: 0.75s تنقيح النتائج
  1. 61
  2. 62
  3. 63

    AMPs are increased in lesional HS, but DCD and other sweat-gland associated proteins are decreased. حسب Margaret Coates (6058580)

    منشور في 2019
    "…<p>(A) Volcano plot showing increased or decreased genes in HS. …"
  4. 64

    mTORC1 hyperactivation led to a decreased autophagic activity in the podocytes. حسب Wakiko Iwata (8600457)

    منشور في 2020
    "…(<b>B</b>) <i>FIP200</i> and <i>ATG101</i> mRNA expressions were decreased in the primary cultured podocytes from <i>Tsc2</i><sup>Δ<i>podocyte</i></sup>. …"
  5. 65
  6. 66

    Time course of central retinal thickness (CRT) in recurrence and non-recurrence groups. حسب Yasuyuki Sotani (20114144)

    منشور في 2025
    "…These values significantly decreased in the first postoperative year to 2.3 ± 2.6, 0.1 ± 0.3, 0.8 ± 1.6, 0, and 3.1 ± 2.8; in the second year to 2.1 ± 2.8, 0.4 ± 1.0, 0.0, 0.1 ± 0.3, and 2.6 ± 2.8; and in the third year to 2.0 ± 2.2, 0, 0.6 ± 1.7, 0.1 ± 0.3, and 2.8 ± 3.5 (Kruskal–Wallis test, p < 0.001; <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0332941#pone.0332941.g007" target="_blank">Fig 7</a>). …"
  7. 67
  8. 68
  9. 69
  10. 70

    Time course of best-corrected visual acuity (BCVA) in recurrence and non-recurrence groups. حسب Yasuyuki Sotani (20114144)

    منشور في 2025
    "…In the non-recurrence group, CRT improved from 482.5 ± 112.8 to 294.7 ± 65.3, 302.0 ± 68.0, 284.7 ± 55.4, 285.3 ± 70.2, 265.2 ± 65.0, and 266.1 ± 78.2 μm at 1, 3, 6, 12, 24, and 36 months, respectively (Kruskal-Wallis test, p < 0.001; <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0332941#pone.0332941.g006" target="_blank">Fig 6</a>).…"
  11. 71
  12. 72
  13. 73
  14. 74

    Table_1_A Strong Decrease in TIMP3 Expression Mediated by the Presence of miR-17 and 20a Enables Extracellular Matrix Remodeling in the NSCLC Lesion Surroundings.DOCX حسب Karolina H. Czarnecka (8121305)

    منشور في 2019
    "…<p>Background: Lung cancer is one of the most common causes of death worldwide with a relatively high fatality rate and a mean 5-years survival of about 18%. …"
  15. 75
  16. 76

    Table 1_Previous treatment decreases efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer.doc حسب Lei Wang (6656)

    منشور في 2025
    "…Background<p>Pralsetinib is a selective RET inhibitor. The ARROW trial revealed that RET fusion-positive non-small-cell lung cancer (NSCLC) can benefit from pralsetinib with tolerable adverse events (AEs). …"
  17. 77
  18. 78
  19. 79
  20. 80